Passage Bio, Inc.
NASDAQ: PASG0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William Chou
- Employees
- 60
- Headquarters
- Philadelphia, United States
- IPO year
- 2020
- Market cap
- $18.9M
- Website
- https://www.passagebio.com
Loading PASG…
Loading profile data…Frequently asked questions about PASG
What does Passage Bio, Inc. (PASG) do?
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid bet...
Where does PASG trade?
Passage Bio, Inc. (PASG) trades on the NASDAQ Global Select.
What sector is PASG in?
Passage Bio, Inc. (PASG) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Passage Bio, Inc.?
William Chou is the chief executive officer of Passage Bio, Inc. (PASG).
Where is Passage Bio, Inc. headquartered?
Passage Bio, Inc. is headquartered in United States.
Does PASG pay a dividend?
Passage Bio, Inc. (PASG) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PASG go public?
Passage Bio, Inc. (PASG) completed its initial public offering in 2020.